116 related articles for article (PubMed ID: 10367788)
1. Platelet function abnormalities in Gaucher disease patients.
Gillis S; Hyam E; Abrahamov A; Elstein D; Zimran A
Am J Hematol; 1999 Jun; 61(2):103-6. PubMed ID: 10367788
[TBL] [Abstract][Full Text] [Related]
2. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
Mitrovic M; Antic D; Elezovic I; Janic D; Miljic P; Sumarac Z; Nikolic T; Suvajdzic N
Platelets; 2012; 23(2):143-9. PubMed ID: 21767238
[TBL] [Abstract][Full Text] [Related]
3. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
Giona F; Palumbo G; Amendola A; Santoro C; Mazzuconi MG
J Thromb Haemost; 2006 Aug; 4(8):1831-3. PubMed ID: 16879228
[No Abstract] [Full Text] [Related]
4. Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleeding.
Spectre G; Roth B; Ronen G; Rosengarten D; Elstein D; Zimran A; Varon D; Revel-Vilk S
Br J Haematol; 2011 May; 153(3):372-8. PubMed ID: 21401572
[TBL] [Abstract][Full Text] [Related]
5. Impaired platelet function and peripartum bleeding in women with Gaucher disease.
Simchen MJ; Oz R; Shenkman B; Zimran A; Elstein D; Kenet G
Thromb Haemost; 2011 Mar; 105(3):509-14. PubMed ID: 21301776
[TBL] [Abstract][Full Text] [Related]
6. Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges.
Komninaka V; Repa K; Marinakis T; Pouliakis A; Koutsouri T; Tsokanas D; Flevary P; Voskaridou E; Politou M
Blood Cells Mol Dis; 2020 Feb; 80():102371. PubMed ID: 31670186
[No Abstract] [Full Text] [Related]
7. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
9. Haemorheology in Gaucher disease.
Bax BE; Richfield L; Bain MD; Mehta AB; Chalmers RA; Rampling MW
Eur J Haematol; 2005 Sep; 75(3):252-8. PubMed ID: 16104883
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.
Hollak CE; Corssmit EP; Aerts JM; Endert E; Sauerwein HP; Romijn JA; van Oers MH
Am J Med; 1997 Sep; 103(3):185-91. PubMed ID: 9316550
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts.
Hayward CP; Moffat KA; Pai M; Liu Y; Seecharan J; McKay H; Webert KE; Cook RJ; Heddle NM
Thromb Haemost; 2008 Jul; 100(1):134-45. PubMed ID: 18612548
[TBL] [Abstract][Full Text] [Related]
12. Complex haemostatic abnormalities as a cause of bleeding after neurosurgery in a patient with Gaucher disease.
Mitrovic M; Elezovic I; Grujicic D; Miljic P; Suvajdzic N
Platelets; 2015; 26(3):260-2. PubMed ID: 24749498
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease.
Givol N; Goldstein G; Peleg O; Shenkman B; Zimran A; Elstein D; Kenet G
Haemophilia; 2012 Jan; 18(1):117-21. PubMed ID: 21545377
[TBL] [Abstract][Full Text] [Related]
14. Enzyme augmentation in moderate to life-threatening Gaucher disease.
Fallet S; Grace ME; Sibille A; Mendelson DS; Shapiro RS; Hermann G; Grabowski GA
Pediatr Res; 1992 May; 31(5):496-502. PubMed ID: 1603627
[TBL] [Abstract][Full Text] [Related]
15. Platelet function and its clinical significance in the myelodysplastic syndromes.
Zeidman A; Sokolover N; Fradin Z; Cohen A; Redlich O; Mittelman M
Hematol J; 2004; 5(3):234-8. PubMed ID: 15167910
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
Weinreb NJ; Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Rosenbloom BE; Scott CR; Wappner RS; Zimran A
Am J Med; 2002 Aug; 113(2):112-9. PubMed ID: 12133749
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
18. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
[TBL] [Abstract][Full Text] [Related]
20. A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis.
Bratosin D; Tissier JP; Lapillonne H; Hermine O; de Villemeur TB; Cotoraci C; Montreuil J; Mignot C
Cytometry B Clin Cytom; 2011 Jan; 80(1):28-37. PubMed ID: 20568298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
